MARKET

EIDX

EIDX

Eidos Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.55
+1.35
+2.99%
After Hours: 46.55 0 0.00% 16:00 11/15 EST
OPEN
45.56
PREV CLOSE
45.20
HIGH
46.65
LOW
44.48
VOLUME
92.37K
TURNOVER
--
52 WEEK HIGH
49.72
52 WEEK LOW
11.15
MARKET CAP
1.67B
P/E (TTM)
-34.0377
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EIDX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EIDX News

  • The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict
  • Benzinga.5d ago
  • Benzinga's Top Upgrades, Downgrades For Npvember 1, 2019
  • Benzinga.11/01 13:45
  • Guggenheim likes Sarepta in premarket analyst action
  • Seeking Alpha - Article.11/01 11:07
  • Barclays Downgrades Eidos Therapeutics to Equal-Weight
  • Benzinga.11/01 10:30

More

Industry

Biotechnology & Medical Research
+1.19%
Pharmaceuticals & Medical Research
+1.32%

Hot Stocks

Name
Price
%Change

About EIDX

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company’s product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.
More

Webull offers Eidos Therapeutics Inc (EIDX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.